Table 4 Summary of the overall treatment-related AEs reported in 24Â months in the OnabotulinumtoxinA 155 U and 195 U groups
|  | OnabotulinumtoxinA 155 U (n = 132) | OnabotulinumtoxinA 195 U (n = 143) | χ 2 | P value |
|---|---|---|---|---|
n (%) | n (%) | |||
Total treatment-related AEs | 23 (17.5) | 29 (20.3) | 0.12 | 0.728 |
Injection-site pain | 4 (3.3) | 5 (3.5) | 0.01 | 0.911 |
Neck pain | 5 (3.8) | 6 (4.2) | 0.03 | 0.868 |
Musculoskeletal weakness | 5 (3.8) | 7 (4.9) | 0.02 | 0.893 |
Eyelid ptosis | 4 (2.9) | 4 (2.8) | 0.01 | 0.911 |
Headache | 5 (3.7) | 7 (4.9) | 0.02 | 0.892 |